F-Prime Capital

Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. We envision a world where all women and their babies have access to safe and effective therapies for treating life threatening complications of pregnancy, and those solutions must be evidence-based and affordable.

Immuneel Therapeutics provides pioneering cell and gene therapies for cancer treatment. They develop CAR-T cell therapies from patients' blood cells by genetically modifying healthy immune cells to target malignant cells, giving cancer patients access to revolutionary cell-based immunotherapies.

Developer of a deep learning platform intended to deliver medicines of transformational efficacy for patients. the company platform delivers transformational medicines through 3D deep learning and cutting-edge drug discovery technologies, enabling doctors in treating undruggable disease targets.

Peptone Ltd develops and provides artificial intelligence (AI) solutions for addressing protein developability problems in biotechnology, biopharmaceutical, and life sciences industries. The company offers antibody designing and optimization, protein database, automated thermos-stability engineering, and hybrid AI deployment solutions. Additionally, it provides CassandraAI, a silico protein engineering platform. Peptone Ltd was founded in 2016 and is headquartered in London, United Kingdom.

SpectrumAi is a digital health company focused on enhancing Autism care by increasing access to high-quality Applied Behavior Analysis (ABA) therapy for children globally. The company collaborates with clinical leaders in ABA therapy, parents, and payers to modernize treatment approaches. SpectrumAi's healthcare technology offers objective data and meaningful insights, providing actionable guidance that empowers patients to work towards independent living, meaningful relationships, lifelong vocation, and self-advocacy. Through its innovative solutions, SpectrumAi aims to provide alternatives for life-changing therapies, ultimately improving outcomes for individuals on the autism spectrum.

Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.

Proof Diagnostics focuses on developing CRISPR-based molecular tests for the detection of COVID-19. The company aims to empower communities by providing rapid diagnostic kits that enable medical professionals to effectively test patients for coronavirus infections. By leveraging advanced genetic technologies, Proof Diagnostics contributes to improved health outcomes and better management of infectious diseases.

Eleos Health is a company that develops a software-as-a-service (SaaS) tool focused on mental health. Utilizing artificial intelligence and voice technology, Eleos Health's platform operates in the background during mental health sessions to gather insights into a patient's behavioral health. By analyzing voice interactions and various data parameters, the tool provides valuable information that enables clinicians to deliver personalized care and support tailored to individual patient needs.

Aerium Therapeutics is discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2 variants.

Expressable is an online speech therapy practice that addresses communication disorders for both children and adults. Founded in 2019 and headquartered in Austin, Texas, the company has developed a parent-focused care model that leverages technology and education to integrate speech therapy techniques into everyday life. The platform offers a range of services, including accent modification, aphasia, apraxia of speech, and support for autism spectrum disorder, among others. By providing weekly practice activities, Expressable aims to enhance speech and language outcomes, enabling individuals to improve their communication skills effectively.

Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.

AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

AppliedVR, Inc. specializes in virtual reality solutions aimed at enhancing patient experiences in healthcare, specifically for managing pain and anxiety in various settings such as hospitals and surgery centers across the United States. Founded in 2013 and based in Los Angeles, the company has established partnerships with leading healthcare institutions, including Cedars-Sinai and Children's Hospital Los Angeles. Its therapeutic virtual reality platform has been utilized by over 20,000 patients in more than 250 hospitals and in eight countries. The technology is designed to address both acute and chronic pain, as well as anxiety related to medical procedures, offering clinically validated, on-demand solutions. Inspired by extensive academic research, AppliedVR seeks to redefine pain management practices in clinical environments and at home, aiming to establish itself as a leading digital health solution provider in this field.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, that specializes in the development of liquid and tissue biopsy analysis platforms aimed at the detection of rare cells. Founded in 2009, RareCyte focuses on providing innovative technologies for the Life Sciences research, drug development, and diagnostic markets. The company offers a range of products, including sample preparation systems, staining kits, and automated fluorescence microscopy instruments. Its AccuCyte system is particularly notable for enabling the unbiased discovery and isolation of circulating tumor cells and circulating endothelial cells from whole blood. RareCyte's technologies are designed to address complex challenges in cancer and cardiovascular disease research, facilitating advancements in precision medicine and non-invasive prenatal testing.

SonderMind LLC, founded in 2017 and based in Denver, Colorado, operates a digital platform that connects individuals with mental health professionals for both telehealth and in-person sessions. The company offers a comprehensive directory of therapists who provide services for a range of mental health issues, including anxiety, depression, PTSD, and more. SonderMind's platform aims to make behavioral health services more accessible and user-friendly, allowing consumers to easily find and schedule appointments with well-matched therapists. By streamlining the connection between clients and providers, SonderMind enhances the therapeutic experience while allowing therapists to concentrate on patient care without being burdened by administrative tasks.

Castor is an international health-tech company that offers a cloud-based clinical data platform designed to streamline the clinical trial process for researchers around the world. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries and has facilitated more than 4,000 studies across diverse therapeutic areas such as diabetes, cardiovascular diseases, rare diseases, infectious diseases, and oncology. Researchers using Castor generate substantial amounts of data from both traditional and remote trials, having reached significant milestones of 180 million data points and 2 million enrolled patients. The company's mission is to enhance the reusability of research data, supporting AI-driven clinical trials and ultimately maximizing the impact of data to improve medical research globally.

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Provider of speech and language therapy services intended for stunted children with speech disorder. The company provides early screening, clinical diagnosis, and therapeutic interventions to children with autism or speech disorder, enabling children to speak and communicate better.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.

Pediatrix Therapeutics is a pharmaceutical company focused on the field of pediatrics by developing and introducing effective and clinically proven children's medicines to provide Chinese children and families with high-quality and affordable treatment options.

Zenflow, Inc. is a medical device company based in San Francisco, California, founded in 2014 by a team of Stanford University Biodesign Fellows in collaboration with leading urologists. The company focuses on developing and marketing a spring device designed to provide relief for permanent benign prostatic hyperplasia (BPH) symptoms in men. Zenflow's product addresses urinary obstruction without damaging surrounding tissues, offering a novel solution for patients and healthcare providers. The founders were motivated by the frustrations experienced by patients with existing treatment options, aiming to fulfill a significant unmet clinical need in urology.

Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

AppliedVR, Inc. specializes in virtual reality solutions aimed at enhancing patient experiences in healthcare, specifically for managing pain and anxiety in various settings such as hospitals and surgery centers across the United States. Founded in 2013 and based in Los Angeles, the company has established partnerships with leading healthcare institutions, including Cedars-Sinai and Children's Hospital Los Angeles. Its therapeutic virtual reality platform has been utilized by over 20,000 patients in more than 250 hospitals and in eight countries. The technology is designed to address both acute and chronic pain, as well as anxiety related to medical procedures, offering clinically validated, on-demand solutions. Inspired by extensive academic research, AppliedVR seeks to redefine pain management practices in clinical environments and at home, aiming to establish itself as a leading digital health solution provider in this field.

Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.

Yisheng Biopharma Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and marketing of immuno-oncology products and vaccines. Founded in 2002 and headquartered in Beijing, the company operates in China, the United States, Cambodia, and Singapore. Yisheng Biopharma utilizes its novel PIKA immunomodulating technology to enhance immune responses against cancers and infectious diseases. Key products under development include YS-ON-001, an investigational therapy aimed at treating advanced solid tumors, as well as YS-HBV-001, a vaccine for hepatitis B, and a PIKA-based rabies vaccine designed for rapid protection against rabies infection. The company's innovative approach targets multiple immune pathways to improve treatment outcomes.

Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited.

Atalanta Therapeutics is a biotechnology company focused on developing innovative treatment options for neurodegenerative diseases through its proprietary RNA interference platform. The company aims to create therapeutics that target various conditions, including Huntington's disease by specifically targeting the HTT gene. By addressing the underlying causes of these diseases, Atalanta Therapeutics seeks to provide clinicians with effective strategies to halt disease progression and improve patient outcomes.

J-Pharma Co., Ltd., founded in 2005 and based in Yokohama, Japan, specializes in the development of therapeutics and diagnostic agents for cancer treatment. The company focuses on a human-genomic approach, creating novel pharmaceuticals that target specific diseases with selective agents. J-Pharma's research emphasizes the role of cell membrane transporters, which are linked to various diseases, particularly in cancer. The company has identified significant drug transporters within the human body that can enhance the evaluation and optimization of pharmacokinetics for new drug candidates. J-Pharma's product pipeline includes anti-cancer drugs and PET diagnostic agents targeting LAT1, a transporter protein associated with cancer cell growth. Through its innovative drug development and diagnostic methods, J-Pharma aims to improve human health and welfare, particularly for the aging population in industrialized nations.

Metcela Inc. specializes in developing fibroblast-based therapies for cardiac diseases, focusing on regenerative medicine for conditions such as Ischemic Heart Disease. Founded in 2016 and based in Kawasaki-shi, Japan, the company utilizes VCAM-1-positive cardiac fibroblasts derived from patients' own cells. This innovative approach aims to replenish and restore damaged cardiac muscle and its surrounding microenvironment, enhancing the heart's natural healing capabilities. By repairing rather than replacing damaged cells, Metcela seeks to provide effective and cost-efficient treatments for heart failure, offering new hope for patients suffering from cardiac ailments.

Citrine Medicine is a rare disease-focused pharmaceutical firm.

Sana Biotechnology is a biotechnology company focused on developing engineered cells as therapies for various diseases. Incorporated in 2018 and based in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company leverages recent scientific advancements to reprogram cells or replace damaged cells and tissues. Sana's mission is to create a new class of medicines that address unmet treatment needs across a wide range of therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Its pipeline includes several product candidates, such as SC291, SC262, SC255, and UP421, aimed at transforming the approach to disease treatment.

Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.

Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.

NFlection Therapeutics, Inc. is a biotechnology company dedicated to developing targeted therapies for rare disorders, particularly those associated with neurofibromatosis type 1 and related conditions. The company specializes in creating novel therapies aimed at addressing the needs of patients suffering from immunosuppressant-mediated squamous cell carcinoma and congenital birthmarks, including keratinocytic epidermal nevi and nevus sebaceous. NFlection focuses on first-in-class MEK inhibitors that target the aberrant activation of the Ras/Raf/MEK/ERK pathway, which is central to these disorders. Founded in 2014 and headquartered in Wayne, Pennsylvania, NFlection Therapeutics is committed to advancing treatments that can significantly impact the lives of patients with these challenging conditions.

NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.

Arvelle Therapeutics GmbH is a biopharmaceutical company based in Zug, Switzerland, founded in 2019. The company focuses on developing and commercializing innovative treatments for patients with central nervous system (CNS) disorders. Its primary product is cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients suffering from focal seizures. By targeting debilitating neurological and neuromuscular diseases, Arvelle Therapeutics aims to enhance the quality of care available to clinicians and their patients.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.

Rallybio, LLC is a biopharmaceutical company based in New Haven, Connecticut, that focuses on developing innovative therapies for patients with severe and rare disorders. Founded in 2018, the company is dedicated to addressing life-threatening conditions, particularly through its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare disease can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's research emphasizes the development of antibody, small molecule, and engineered protein therapies, primarily in the late discovery to early clinical stages. Through its efforts, Rallybio seeks to transform the lives of patients suffering from devastating diseases.

SonderMind LLC, founded in 2017 and based in Denver, Colorado, operates a digital platform that connects individuals with mental health professionals for both telehealth and in-person sessions. The company offers a comprehensive directory of therapists who provide services for a range of mental health issues, including anxiety, depression, PTSD, and more. SonderMind's platform aims to make behavioral health services more accessible and user-friendly, allowing consumers to easily find and schedule appointments with well-matched therapists. By streamlining the connection between clients and providers, SonderMind enhances the therapeutic experience while allowing therapists to concentrate on patient care without being burdened by administrative tasks.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for various diseases, particularly those affecting muscle and the central nervous system (CNS). Founded in 2019 and based in Waltham, Massachusetts, the company specializes in creating rationally designed adeno-associated virus (AAV) vectors. By integrating synthetic and systems biology with high-throughput screening and advanced resolution techniques, Affinia Therapeutics aims to address significant unmet medical needs. The company’s innovative approach allows for the development of novel gene therapies with enhanced properties, targeting the treatment of devastating diseases and improving the lives of affected individuals.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.

Adagene (Suzhou) Limited is a clinical-stage biotechnology company based in Suzhou, China, focused on antibody discovery and engineering. The company specializes in developing immuno-oncology antibodies that target novel epitopes, utilizing its proprietary Smart Antibody Technology. This technology enhances the success rates of antibody development, significantly shortens the time required to bring products to market, and lowers associated costs. Adagene's offerings extend beyond therapeutic applications, as its technology is also applicable in diagnostics and research, aiming to advance the field of immunotherapy and improve patient outcomes. Founded in 2011, Adagene continues to innovate in the biopharmaceutical sector.

Immuneel Therapeutics provides pioneering cell and gene therapies for cancer treatment. They develop CAR-T cell therapies from patients' blood cells by genetically modifying healthy immune cells to target malignant cells, giving cancer patients access to revolutionary cell-based immunotherapies.

AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.

Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.

Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.

Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. The company focuses on developing novel therapeutics called "nocions," which are designed to treat conditions associated with neurogenic inflammation. These nocions specifically target activated sensory neurons, entering nociceptors through large-pore channels that open in response to stimulation. This mechanism allows for the selective blocking of sodium channels, providing targeted and sustained relief for serious conditions such as cough, itch, pain, and inflammation. By offering an alternative to traditional small molecule anesthetics, Nocion Therapeutics aims to deliver more effective treatment options for patients suffering from these debilitating symptoms.

ABK Biomedical Inc., founded in 2012 and based in Halifax, Canada, develops innovative embolotherapeutic products aimed at treating uterine fibroids, hypervascular tumors, and arteriovenous malformations. The company focuses on enhancing interventional radiology procedures, particularly embolization, by combining clinical market insights with advanced biomaterials. ABK Biomedical's flagship product is a novel radiopaque microsphere designed to improve the targeting of tumor blood vessels and tissue. This technology not only aids in the standardization and optimization of minimally invasive therapies but also facilitates personalized treatment options for patients with complex conditions. Through its commitment to advancing embolotherapy, ABK Biomedical seeks to transform patient care in the field of interventional radiology.

ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR. The company develops drugs focused on novel small molecules for multiple unmet medical needs. ShouTi is currently operating in Stealth mode.

Artemis Health Inc. is a health data analytics company that specializes in providing self-insured employers with actionable insights into their employee benefit programs. Founded in 2013 and headquartered in Salt Lake City, Utah, the company offers a platform that helps employers identify issues within their benefits programs, pinpoint opportunities for improvement, and track the effectiveness of implemented solutions. By leveraging their own benefits data, employers can make informed decisions aimed at reducing healthcare expenditures while enhancing the quality of health and wellness coverage for their employees. Artemis Health's approach aims to address inefficiencies in the U.S. healthcare system, ultimately supporting organizations in optimizing their benefit offerings.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. This technology allows for targeted alterations of single bases in the genome without creating double-stranded breaks in DNA, representing a potential advancement in genetic therapies. The company's pipeline includes programs aimed at treating serious diseases such as sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, and pediatric acute myeloid leukemia, as well as conditions like alpha-1 antitrypsin deficiency and certain central nervous system disorders. Beam Therapeutics is committed to providing life-long cures through its various approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Founded in 2017, Beam continues to build collaborations to enhance its research and development efforts.

TreeENT Health, established in 2017 and based in Hangzhou, China, operates as a specialized surgical center focusing on ear, nose, and throat (ENT) conditions. The company, also known as Renshu Medical, provides a comprehensive range of services for various ENT diseases, including suppurative otitis media, allergic rhinitis, chronic sinusitis, and thyroid cancer. Utilizing advanced technology, TreeENT offers minimally invasive surgical procedures, as well as diagnostic services such as Danish ear hearing detection, nasal endoscopy, and nasopharyngoscopy. Additionally, the company facilitates patient access through WeChat for appointment scheduling with medical experts. With a commitment to high-quality care, TreeENT aims to deliver professional medical services that align with international standards and support personalized chronic disease rehabilitation.

Sana Biotechnology is a biotechnology company focused on developing engineered cells as therapies for various diseases. Incorporated in 2018 and based in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company leverages recent scientific advancements to reprogram cells or replace damaged cells and tissues. Sana's mission is to create a new class of medicines that address unmet treatment needs across a wide range of therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Its pipeline includes several product candidates, such as SC291, SC262, SC255, and UP421, aimed at transforming the approach to disease treatment.

Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.

Genomics PLC is focused on advancing the use of genomic data to transform healthcare. The company develops algorithms and software solutions that facilitate the analysis of large genomic and phenotypic datasets, aimed at understanding human biology and improving disease diagnosis and treatment. Its offerings serve a diverse range of clients, including governments, healthcare providers, pharmaceutical companies, and research laboratories. By providing tools that enhance the accuracy of genetic analysis, Genomics PLC helps de-risk the drug development process and enables clinicians to better identify individuals at risk for specific diseases. Founded in 2014 and based in Oxford, United Kingdom, the company aims to set standards in genomic data application, ultimately benefiting organizations and patients alike through innovative healthcare solutions.

Avidity Biosciences is a biopharmaceutical company specializing in the development of oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disorder. The company's development pipeline also includes programs focused on treating various muscle diseases, such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Additionally, Avidity is exploring therapeutic applications for immune and other cell types, leveraging its proprietary AOC platform to reach previously undruggable tissues and effectively target the genetic underpinnings of these conditions. Founded in 2012, Avidity Biosciences is headquartered in La Jolla, California.

Modis Therapeutics, Inc. is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with significant unmet medical needs. The company, based in Oakland, California, was incorporated in 2016 and is a subsidiary of Zogenix, Inc. Modis Therapeutics is advancing its lead therapy, MT1621, which aims to restore mitochondrial DNA replication fidelity. This therapeutic candidate is specifically designed to address thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disorder. By improving nucleotide balance, increasing mitochondrial DNA copy number, and enhancing cell function, Modis Therapeutics aims to provide meaningful treatment options that can prolong the lives of affected patients.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Metcela Inc. specializes in developing fibroblast-based therapies for cardiac diseases, focusing on regenerative medicine for conditions such as Ischemic Heart Disease. Founded in 2016 and based in Kawasaki-shi, Japan, the company utilizes VCAM-1-positive cardiac fibroblasts derived from patients' own cells. This innovative approach aims to replenish and restore damaged cardiac muscle and its surrounding microenvironment, enhancing the heart's natural healing capabilities. By repairing rather than replacing damaged cells, Metcela seeks to provide effective and cost-efficient treatments for heart failure, offering new hope for patients suffering from cardiac ailments.

TraceLink, Inc. specializes in providing track and trace network solutions that enhance the life sciences supply chain and combat counterfeit prescription drugs. The company offers a range of products, including pharmaceutical serialization, drug tracking, and compliance solutions through its TraceLink Life Sciences Cloud. Key offerings include the Smart Rx Manager, which helps healthcare providers comply with the European Union Falsified Medicines Directive, and Serialized Product Intelligence, a cloud application that utilizes serialization data to identify supply chain issues and optimize operations. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers, and has established strategic partnerships with notable firms such as Amazon and KPMG. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink also has offices in the United Kingdom, India, Singapore, and Brazil. The company's platform is recognized for its ability to deliver global connectivity and visibility across the pharmaceutical supply chain, ensuring compliance and improving operational efficiency.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and discovering therapeutic antibodies for the treatment of solid tumors and hematological malignancies. The company's lead product candidate, CTX-471, is a fully human monoclonal antibody that acts as an agonist of CD137, currently undergoing Phase I clinical trials for patients who have had inadequate responses to existing PD-1/PD-L1 checkpoint inhibitors. In addition to CTX-471, Compass is advancing several preclinical assets, including CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, and CTX-8573, designed to engage natural killer (NK) cells against B cell maturation antigen, which is prevalent in multiple myeloma. Founded in 2014, Compass Therapeutics is headquartered in Cambridge, Massachusetts, and employs innovative platforms to enhance the efficacy of its antibody therapeutics.

Sana Biotechnology is a biotechnology company focused on developing engineered cells as therapies for various diseases. Incorporated in 2018 and based in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company leverages recent scientific advancements to reprogram cells or replace damaged cells and tissues. Sana's mission is to create a new class of medicines that address unmet treatment needs across a wide range of therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Its pipeline includes several product candidates, such as SC291, SC262, SC255, and UP421, aimed at transforming the approach to disease treatment.

NodThera Limited is a biotechnology company focused on researching and developing novel inhibitors of the NLRP3 inflammasome, which play a critical role in inflammatory and neuroinflammatory diseases. Established in 2016 and headquartered in Little Chesterford, United Kingdom, NodThera operates a laboratory in Seattle, Washington, and a corporate office in Lexington, Massachusetts. The company aims to create therapies targeting a range of conditions including arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. By developing potent and selective NLRP3 inflammasome inhibitors, NodThera seeks to reduce pro-inflammatory cytokines, enabling more effective treatment options for patients suffering from chronic inflammation-related diseases.

TraceLink, Inc. specializes in providing track and trace network solutions that enhance the life sciences supply chain and combat counterfeit prescription drugs. The company offers a range of products, including pharmaceutical serialization, drug tracking, and compliance solutions through its TraceLink Life Sciences Cloud. Key offerings include the Smart Rx Manager, which helps healthcare providers comply with the European Union Falsified Medicines Directive, and Serialized Product Intelligence, a cloud application that utilizes serialization data to identify supply chain issues and optimize operations. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers, and has established strategic partnerships with notable firms such as Amazon and KPMG. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink also has offices in the United Kingdom, India, Singapore, and Brazil. The company's platform is recognized for its ability to deliver global connectivity and visibility across the pharmaceutical supply chain, ensuring compliance and improving operational efficiency.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, specializing in primary care services across the United States. Founded in 2010, the company is committed to overcoming the barriers typically present in the healthcare system by offering personalized care for each patient. Each individual is assigned a dedicated personal physician and health coach, who maintain regular communication through various channels, including email, text, and video, in addition to in-person consultations. Iora Health employs a team-based approach that includes a doctor or nurse practitioner, nurse, behavioral health specialist, and health coach, all supported by a proprietary technology platform for effective population health management. The organization also provides educational programs, such as group visits, to assist patients in achieving their health goals and managing their overall well-being.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. This technology allows for targeted alterations of single bases in the genome without creating double-stranded breaks in DNA, representing a potential advancement in genetic therapies. The company's pipeline includes programs aimed at treating serious diseases such as sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, and pediatric acute myeloid leukemia, as well as conditions like alpha-1 antitrypsin deficiency and certain central nervous system disorders. Beam Therapeutics is committed to providing life-long cures through its various approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Founded in 2017, Beam continues to build collaborations to enhance its research and development efforts.

Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.

Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.

Zenflow, Inc. is a medical device company based in San Francisco, California, founded in 2014 by a team of Stanford University Biodesign Fellows in collaboration with leading urologists. The company focuses on developing and marketing a spring device designed to provide relief for permanent benign prostatic hyperplasia (BPH) symptoms in men. Zenflow's product addresses urinary obstruction without damaging surrounding tissues, offering a novel solution for patients and healthcare providers. The founders were motivated by the frustrations experienced by patients with existing treatment options, aiming to fulfill a significant unmet clinical need in urology.

Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.

Biopalette is a operator of a platform intended to offer gene-editing techniques. Bio Palette plans to develop our business in three fields, classified based on the type of cells targeted for genome editing.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. Operating in the United Kingdom, European Union, and the United States, Orchard employs an autologous ex vivo gene therapy approach to transform patients’ hematopoietic stem cells into gene-modified products for treatment through a single administration. Its portfolio includes Strimvelis, the first approved gene therapy for adenosine deaminase-severe combined immunodeficiency (ADA-SCID), along with several products in clinical development targeting metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has a robust preclinical pipeline addressing various mucopolysaccharidosis types. Orchard collaborates with leading institutions in gene therapy, enhancing its research capabilities and clinical programs. Founded in 2015, Orchard Therapeutics continues to demonstrate a commitment to transforming the lives of patients through its advanced therapies.

Provider of speech and language therapy services intended for stunted children with speech disorder. The company provides early screening, clinical diagnosis, and therapeutic interventions to children with autism or speech disorder, enabling children to speak and communicate better.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.

Artemis Health Inc. is a health data analytics company that specializes in providing self-insured employers with actionable insights into their employee benefit programs. Founded in 2013 and headquartered in Salt Lake City, Utah, the company offers a platform that helps employers identify issues within their benefits programs, pinpoint opportunities for improvement, and track the effectiveness of implemented solutions. By leveraging their own benefits data, employers can make informed decisions aimed at reducing healthcare expenditures while enhancing the quality of health and wellness coverage for their employees. Artemis Health's approach aims to address inefficiencies in the U.S. healthcare system, ultimately supporting organizations in optimizing their benefit offerings.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing therapeutic compounds that inhibit the complement system to address autoimmune and inflammatory diseases. The company's lead candidate, pegcetacoplan, is undergoing Phase III clinical trials for geographic atrophy associated with age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, while also being assessed in Phase II trials for several other conditions, including cold agglutinin disease and lupus nephritis. Additionally, Apellis is developing APL-9, which is currently in Phase I clinical trials aimed at preventing immune activation related to adeno-associated virus. The company collaborates with Swedish Orphan Biovitrum AB to advance pegcetacoplan for various rare diseases. Founded in 2009, Apellis focuses on creating innovative therapies for conditions characterized by excessive activation of the complement cascade across multiple medical fields, including hematology and ophthalmology.

Indalo Therapeutics is a preclinical-stage biotechnology company focused on developing innovative therapies for patients afflicted by fibrotic diseases. Founded on significant scientific advancements, the company leverages deep insights into the molecular mechanisms that drive abnormal scarring. By assembling a skilled team of pharmaceutical scientists and industry executives, Indalo aims to address critical unmet medical needs in the field of fibrosis. Its therapeutic approach seeks to not only halt but also potentially reverse the progression of fibrotic conditions, ultimately improving the quality of life for affected individuals.

PlasmaGen Biosciences Pvt. Ltd. is an Indian bio-pharmaceutical company based in Bengaluru, specializing in the manufacture of plasma-derived products and therapies. Established in 2010, the company develops a range of plasma protein therapies, including PlasmaGlob and AlbuMax, which are Normal Human Immunoglobulin formulations for intravenous use. Their product portfolio also includes PlasmaRho-D I.V. for Rho (D) immunization, PlasmaRAB for rabies post-exposure prophylaxis, and PlasmaHep for various hepatitis B-related indications. Additionally, PlasmaGen offers VerBumin for conditions such as hypovolemic shock and plasma exchange dialysis. The company serves a diverse clientele, including clinicians, medical practitioners, corporate hospitals, and government institutions, positioning itself as a key provider of plasma products across various medical fields, including hematology, oncology, and immunology.

Amphora Medical, Inc. is a Minnesota-based company that develops medical devices focused on treating female overactive bladder (OAB) syndrome. Founded in 2011 and headquartered in Maple Grove, Minnesota, the company is working on a novel cystoscopic device designed to enhance bladder function and improve the quality of life for patients suffering from OAB. Utilizing minimally invasive procedures and advanced cystoscopic technology, Amphora Medical aims to provide effective solutions for individuals affected by this condition.

VYNE Therapeutics is a late-stage biopharmaceutical company that specializes in the development and commercialization of serlopitant, a treatment for pruritus associated with various dermatologic conditions, including atopic dermatitis, psoriasis, and prurigo nodularis. The company aims to address a significant unmet medical need, as there are currently no approved therapies in the United States that specifically target pruritus in these conditions. In addition to its focus on dermatologic applications, VYNE is also investigating serlopitant for refractory chronic cough, a persistent cough that lasts more than eight weeks despite treatment. Serlopitant acts as a selective small molecule inhibitor of the neurokinin 1 receptor and is administered as an oral tablet once daily. The company has completed Phase II clinical trials for pruritus related to various conditions and is planning to advance into Phase III trials for prurigo nodularis, anticipating further data to support its clinical development. VYNE Therapeutics is headquartered in Redwood City, California, and was established in 2011.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and discovering therapeutic antibodies for the treatment of solid tumors and hematological malignancies. The company's lead product candidate, CTX-471, is a fully human monoclonal antibody that acts as an agonist of CD137, currently undergoing Phase I clinical trials for patients who have had inadequate responses to existing PD-1/PD-L1 checkpoint inhibitors. In addition to CTX-471, Compass is advancing several preclinical assets, including CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, and CTX-8573, designed to engage natural killer (NK) cells against B cell maturation antigen, which is prevalent in multiple myeloma. Founded in 2014, Compass Therapeutics is headquartered in Cambridge, Massachusetts, and employs innovative platforms to enhance the efficacy of its antibody therapeutics.

Checkmate Pharmaceuticals is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that specializes in developing novel immunotherapies for cancer treatment. Founded in 2015, the company focuses on leveraging CpG oligonucleotides to enhance anti-tumor T-cell responses and overcome the mechanisms that allow tumors to evade immune detection. By combining its proprietary technology with checkpoint inhibition, Checkmate aims to improve the efficacy of existing immunotherapies and provide new treatment options for patients. The company has formed strategic alliances with major pharmaceutical firms, including Merck KGaA and Pfizer, to further its research and development efforts in the field of cancer immunotherapy.

Biopalette is a operator of a platform intended to offer gene-editing techniques. Bio Palette plans to develop our business in three fields, classified based on the type of cells targeted for genome editing.

Genoa Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF). It develops GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. The company was founded in 2011 and is based in San Diego, California.

Biopalette is a operator of a platform intended to offer gene-editing techniques. Bio Palette plans to develop our business in three fields, classified based on the type of cells targeted for genome editing.

Medwell Ventures Private Limited is a provider of specialty home healthcare services in India, focusing on a range of therapeutic areas. Established in 2014 and headquartered in Bengaluru, the company offers a variety of wellness and care programs, including preventive screening, palliative care, and bedside nursing. Its services encompass 24×7 medical support, physician consultations, nursing care, laboratory sample collection and reporting, physiotherapy, medical devices, ambulance services, and pharmacy support. By integrating different healthcare delivery channels, Medwell Ventures aims to enhance the accessibility and personalization of medical treatment for patients with chronic diseases and diverse health profiles.

Promentis Pharmaceuticals, Inc. is a biopharmaceutical company based in Milwaukee, Wisconsin, established in 2006. The company specializes in developing therapies for neuropsychiatric disorders, with a focus on addressing glutamatergic imbalance and oxidative stress. Promentis is known for its lead compound, SXC-2023, which targets System xc- to treat multiple conditions, including impulse control disorders and obsessive-compulsive disorder. In addition to SXC-2023, Promentis is also working on other compounds aimed at restoring glutamatergic neurotransmission, which is crucial for improving cortical function and managing various psychiatric disorders, including schizophrenia.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing therapies for idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company is advancing inhaled formulations of pirfenidone, specifically AP01, which aims to enhance drug delivery to the lungs while potentially reducing side effects associated with oral treatments. This innovative approach seeks to improve the care and outcomes for patients suffering from these conditions. Established in 2011, Avalyn Pharma operates from its headquarters in Seattle, Washington, and maintains an additional office in San Diego, California. The company was previously known as Genoa Pharmaceuticals, Inc. before rebranding in July 2017.

Core Diagnostics Private Limited is a clinical laboratory based in Gurugram, India, established in 2012. The company specializes in next-generation diagnostics aimed at disease stratification and therapy selection. By employing advanced testing techniques, Core Diagnostics seeks to provide comprehensive diagnostic solutions and become a leading provider of high-end diagnostic services in the region.

TraceLink, Inc. specializes in providing track and trace network solutions that enhance the life sciences supply chain and combat counterfeit prescription drugs. The company offers a range of products, including pharmaceutical serialization, drug tracking, and compliance solutions through its TraceLink Life Sciences Cloud. Key offerings include the Smart Rx Manager, which helps healthcare providers comply with the European Union Falsified Medicines Directive, and Serialized Product Intelligence, a cloud application that utilizes serialization data to identify supply chain issues and optimize operations. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers, and has established strategic partnerships with notable firms such as Amazon and KPMG. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink also has offices in the United Kingdom, India, Singapore, and Brazil. The company's platform is recognized for its ability to deliver global connectivity and visibility across the pharmaceutical supply chain, ensuring compliance and improving operational efficiency.